|
Volumn 348, Issue 6230, 2015, Pages 69-74
|
Neoantigens in cancer immunotherapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
TUMOR ANTIGEN;
TUMOR MARKER;
ANTIGEN;
BIOMARKER;
CANCER;
IMMUNIZATION;
INNOVATION;
MUTATION;
TUMOR;
ADAPTIVE IMMUNITY;
ALLELE;
CANCER IMMUNOTHERAPY;
ENDOPLASMIC RETICULUM;
EXOME;
GENE MUTATION;
GENETIC DAMAGE;
HUMAN;
IMMUNOGENICITY;
INNATE IMMUNITY;
MAJOR HISTOCOMPATIBILITY COMPLEX;
MASS SPECTROMETRY;
MELANOMA;
NONHUMAN;
OPEN READING FRAME;
PREDICTION;
PRIORITY JOURNAL;
REVIEW;
RNA SEQUENCE;
SOMATIC MUTATION;
TUMOR ASSOCIATED LEUKOCYTE;
TUMOR IMMUNITY;
FEMALE;
GENETICS;
IMMUNOLOGY;
IMMUNOTHERAPY;
MUTATION;
NEOPLASMS;
NUCLEOTIDE SEQUENCE;
PROCEDURES;
T LYMPHOCYTE;
TUMOR GENE;
ANTIGENS, NEOPLASM;
DNA MUTATIONAL ANALYSIS;
EXOME;
FEMALE;
GENES, NEOPLASM;
HUMANS;
IMMUNOTHERAPY;
MUTATION;
NEOPLASMS;
T-LYMPHOCYTES;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 84928770388
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.aaa4971 Document Type: Review |
Times cited : (3680)
|
References (52)
|